First Test Launched, Theranostics Focuses on Reimbursements as it Builds Commercial Operations | GenomeWeb

NEW YORK (GenomeWeb News) – Months removed from the commercial launch of its first test, Theranostics Health is targeting reimbursements as it looks to build a revenue stream for the test.

The Rockville, Md.-based firm launched the TheraLink HER Family Assay at the American Society of Clinical Oncology annual meeting in June, marking the next chapter in Theranostics' commercial build-out.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.